Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

ConditionBlood Cancer

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age16-65

SponsorUniversity College, London

About this trial

KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.

Eligibility criteria

Qualifiers

Age 16-65 years

CD19+ disease

Agreement to have a pregnancy test, use adequate contraception (if applicable)

Written informed consent

Disqualifiers

CD19 negative disease

Active CNS involvement of disease

Diagnosis of chronic lymphocytic leukaemia/ small lymphocytic lymphoma or Burkitt lymphoma

Active hepatitis B, C or HIV infection

Trial design

Treatments tested in this trial

KCAT19 T cells

Treatment groups

12 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

University College, London

Lead sponsor

Source ClinicalTrials.gov